Department of Laboratory Medicine, Key Laboratory of Diagnostic Medicine (Ministry of Education), Chongqing Medical University, Chongqing 400016, People's Republic of China.
Infect Immun. 2010 Mar;78(3):1276-83. doi: 10.1128/IAI.00473-09. Epub 2009 Dec 28.
Pneumococcal polysaccharide-based vaccines are effective in preventing pneumococcus infection; however, some drawbacks preclude their widespread use in developing and undeveloped countries. Here, we evaluated the protective effects of ATP-dependent caseinolytic protease (ClpP), pneumolysin mutant (DeltaA146 Ply), putative lipoate-protein ligase (Lpl), or combinations thereof against pneumococcal infections in mice. Vaccinated mice were intraperitoneally and/or intranasally challenged with different pneumococcal strains. In intraperitoneal challenge models with pneumococcal strain D39 (serotype 2), the most striking protection was obtained with the combination of the three antigens. Similarly, with the intranasal challenge models, (i) additive clearance of bacteria in lungs was observed for the combination of the three antigens and (ii) a combination vaccine conferred complete protection against intranasal infections of three of the four most common pneumococcal strains (serotypes 14, 19F, and 23F) and 80% protection for pneumococcal strain 6B. Even so, immunity to this combination could confer protection against pneumococcal infection with a mixture of four serotypes. Our results showed that the combination vaccine was as effective as the currently used vaccines (PCV7 and PPV23). These results indicate that system immunization with the combination of pneumococcal antigens could provide an additive and broad protection against Streptococcus pneumoniae in pneumonia and sepsis infection models.
肺炎球菌多糖疫苗在预防肺炎球菌感染方面具有良好的效果,但由于某些缺点,其在发展中国家和不发达国家的广泛使用受到限制。在此,我们评估了 ATP 依赖的蛋白酶体(ClpP)、肺炎球菌溶血素突变体(DeltaA146 Ply)、潜在的脂酰-蛋白连接酶(Lpl)或它们的组合在小鼠肺炎球菌感染中的保护作用。接种疫苗的小鼠通过腹膜内和/或鼻内途径接受不同肺炎球菌菌株的攻击。在肺炎球菌菌株 D39(血清型 2)的腹膜内攻击模型中,三种抗原的联合使用提供了最显著的保护作用。同样,在鼻内攻击模型中,(i)三种抗原的联合使用观察到肺部细菌清除的累加效应,(ii)联合疫苗对四种最常见肺炎球菌菌株(血清型 14、19F 和 23F)中的三种以及对肺炎球菌菌株 6B 提供了完全的鼻内感染保护,保护率为 80%。即便如此,对这种组合的免疫可以提供对混合四种血清型的肺炎球菌感染的保护。我们的结果表明,联合疫苗与目前使用的疫苗(PCV7 和 PPV23)一样有效。这些结果表明,肺炎球菌抗原的联合系统免疫可以在肺炎和脓毒症感染模型中提供针对肺炎链球菌的累加和广泛保护。